Du är här

2014-04-17

RECORDATI : SHAREHOLDERS APPROVE THE 2013 ACCOUNTS. DIVIDEND € 0.33 PER SHARE.

RECORDATI: SHAREHOLDERS APPROVE THE 2013 ACCOUNTS. DIVIDEND € 0.33 PER SHARE.

* Shareholders approve the 2013 results: Consolidated revenue € 941.6
million, +13.7%, operating income € 195.4 million, +17.0%, net income €
133.7 million, +12.8%.
* Dividend for 2013 € 0.33 per share (€ 0.30 in the preceding year), of which
€ 0.22 already paid in November 2013.
* Appointment of the Board of Directors, 60% of which independent, for the
2014-2016 three-year period.
* Appointment of the Board of Statutory Auditors for the 2014-2016 three-year
period.
* Remuneration policy approved.
* New 2014-2018 stock option plan approved.
* Authorization to buy-back and dispose of Recordati shares renewed.
* First quarter 2014 consolidated revenue € 260.4 million (+6.5%).

Milan, 17 April 2014 -
Today the Annual Meeting of Recordati Shareholders was held.

Recordati's Annual Shareholders' Meeting approved the company's 2013 financial
accounts which were prepared according to IAS/IFRS. In addition, the group's
consolidated statements, which were also prepared according to IAS/IFRS, were
presented. The tables attached contain a summary of the 2013 financial
statements. As announced on 6 March 2014 revenues are € 941.6 million
(+13.7%), operating income (EBIT) is € 195.4 million (+17.0%), and net income
is € 133.7 million (+12.8%). International sales account for 75.7% of total
sales.

As proposed by the Board of Directors, the shareholders approved a dividend of
€ 0.11 per share (before withholding tax), in full balance of the interim
2013 dividend of € 0.22, to be paid to all shares outstanding at ex-dividend
date, excluding those in treasury stock, as from 2 May 2014 and record date
on 30 April 2014, with ex-dividend on 28 April 2014. The full 2013 dividend
is therefore of € 0.33 per share (€ 0.30 per share last year).

Further shareholder resolutions

Appointment of the members of the Board of Directors and Board of Statutory
Auditors

The shareholders appointed the Board of Directors for the years 2014, 2015 and
2016 (until the Annual Shareholders' Meeting which will approve the 2016
financial statements) which is composed of ten members. Nominees to the Board
include the new members Rosalba Casiraghi, Michaela Castelli and Paolo
Fresia. The following members were re-elected: Giovanni Recordati, Alberto
Recordati, Andrea Recordati, Fritz Squindo, Marco Vitale, Mario Garraffo and
Carlo Pedersoli. The newly elected member Paolo Fresia was taken from the
proposal presented by shareholder Torre S.S., while all the other nominees
were chosen among the candidates proposed by the majority shareholder FIMEI
S.p.A.. The shareholders, furthermore, appointed the Statutory Auditors by
approving the proposal presented by the majority shareholder FIMEI S.p.A. to
confirm Marco Nava, President and Marco Rigotti, Auditor and to nominate the
new Auditor Livia Amidani Aliberti. Marco Antonio Viganò was re-elected
Alternate Auditor and Patrizia Oriundi Paleologo appointed new Alternate
Auditor.

The professional résumés of the members of the new Board of Directors and the
new Statutory Auditors are available on the company's website:
http://www.recordati.it/investors/shareholders_meetings/2014sm.aspx?sc_l....

Remuneration policy

The Shareholders' Meeting also approved the remuneration policies in
accordance with article 123ter
of Legislative Decree No. 58 of 24 February 1998 which is the object of the
Board's explanatory report on the fourth item of the agenda of the
Shareholders' Meeting and can be found on the company's website at:

http://www.recordati.it/investors/shareholders_meetings/2014sm.aspx?sc_l....

New 2014-2018 stock option plan

Furthermore, the Shareholders' Meeting approved a new stock option plan
covering the five year 2014-2018 period, the details of which have already
been published and communicated to the public and are available in the
relative explanatory document as required by law. The explanatory document,
which is the object of the Board's explanatory report on the fifth item of
the agenda of the Shareholders' Meeting, can be found on the company's
website at:
http://www.recordati.it/investors/shareholders_meetings/2014sm.aspx?sc_l....

Authorization to buy-back and dispose of Recordati shares

The Shareholders' Meeting authorized the buy back and disposal of Recordati
shares until the Annual Shareholders' Meeting which will approve the 2014
financial statements. The objective of the proposal to renew the
authorization to buy back and dispose of Recordati shares until the Annual
Shareholders' Meeting which will approve the 2014 financial statements is, as
in previous years, to grant the Board the possibility: of using shares for
equity acquisitions or as consideration for strategic agreements; of allowing
the company to invest in its own shares; and of constituting a stock of own
shares to service current and future stock option plans. The company would be
allowed to purchase up to 20,000,000 Recordati existing ordinary (common)
shares, which includes those shares held in Treasury stock at any given time,
for a maximum cash outlay of € 250,000,000. The purchase price must be at
least equal to the shares' nominal value (€ 0.125) and must not exceed the
average official Stock Exchange price recorded over the 5 trading days prior
to the transaction, plus 5%. Possible purchases will be made on regulated
markets and must comply with article 132 of Legislative Decree 58/1998 and
with article 144-bis, comma 1.b) of the Issuers' Regulations as approved by
CONSOB's resolution 11971/1999 and with market practice allowed and
recognized by CONSOB. As at 16 April 2014 the company has 6,255,110 shares
in Treasury stock which amounts to 2.991% of the current share capital.

Meeting of the Board of Directors following the Shareholders' Meeting

The new Board of Directors, in a meeting held following the Shareholders'
Meeting, confirmed Giovanni Recordati as Chairman and CEO, with the same
powers granted during the previous mandate, and Alberto Recordati as Vice
Chairman. The Board therefore confirmed, taking into account their functions,
Giovanni Recordati, Chairman and CEO, Alberto Recordati, Vice Chairman,
Andrea Recordati and Fritz Squindo as executive directors.

The Board, using as a basis the Directors' statements and available
information, verified the effective existence of the independence requisites,
pursuant both to Legislative Decree 58/1998 and to the Corporate Governance
Code adopted by the company (see the Corporate Governance and Ownership
Structure Report for 2013), concerning the Directors who declared to possess
such requisites (Rosalba Casiraghi, Michaela Castelli, Paolo Fresia, Mario
Garraffo, Carlo Pedersoli and Marco Vitale; all qualifying as independent).
Sixty percent of the Board of Directors is therefore composed of independent
members.

The Board also verified and confirmed the effective existence of the
independence requisites, pursuant to Legislative Decree 58/1998, of the
Statutory Auditors who also declared to possess the independence requisites
as per article 3 of the Corporate Governance Code as adopted by the company.

Finally, the independent Directors Marco Vitale as President, Mario Garraffo
and Carlo Pedersoli were appointed as members of the Audit and Risk
Committee, while Mario Garraffo as President, Rosalba Casiraghi and Michaela
Castelli were appointed to the Remuneration Committee. The activities which
the Corporate Governance Code assigns to the Nomination Committee will be
carried out by the entire Board of Directors.

First quarter 2014

Revenue performance in the first quarter 2014 is positive. Group sales are €
260.4 million, an increase of 6.5% over those in the first quarter of the
preceding year.

Recordati

, established in 1926, is an international pharmaceutical group, listed on the
Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT
0003828271), with a total staff of around 4,000, dedicated to the research,
development, manufacturing and marketing of pharmaceuticals. Headquartered in
Milan, Italy, Recordati has operations in the main European countries, in
Russia, in other Central and Eastern European countries, in Turkey, in North
Africa and in the United States of America. An efficient field force of
medical representatives promotes a wide range of innovative pharmaceuticals,
both proprietary and under license, in a number of therapeutic areas
including a specialized business dedicated to treatments for rare diseases.
Recordati is a partner of choice for new product licenses for its
territories. Recordati is committed to the research and development of new
specialties within the urogenital therapeutic area and of treatments for rare
diseases. Consolidated revenue for 2013 was € 941.6 million, operating
income was € 195.4 million and net income was € 133.7 million.

For further information:

Recordati website: www.recordati.com

Investor Relations Media
Relations
Marianne Tatschke Ketchum

(39)0248787393
Cristina Risciotti, (39)0262411919,cristina.risciotti@ketchum.com

e-mail:inver@recordati.it Marzia
Ongaretti, (39)0262411915,marzia.ongaretti@ketchum.com

S
tatements contained in this release, other than historical facts, are
"forward-looking statements" (as such term is defined in the Private
Securities Litigation Reform Act of 1995). These statements are based on
currently available information, on current best estimates, and on
assumptions believed to be reasonable. This information, these estimates and
assumptions may prove to be incomplete or erroneous, and involve numerous
risks and uncertainties, beyond the Company's control. Hence, actual results
may differ materially from those expressed or implied by such forward-looking
statements. All mentions and descriptions of Recordati products are intended
solely as information on the general nature of the company's activities and
are not intended to indicate the advisability of administering any product in
any particular instance.

RECORDATI GROUP

Summary of consolidated results prepared in accordance with the International
Accounting Standards and International Financial Reporting Standards
(IAS/IFRS)
(thousands of €)

-----------------------------------------------------------------
|INCOME STATEMENT 2013 2012 Change % |
|REVENUE 941,630 828,317 13.7 |
|Cost of sales (327,329) (293,557) 11.5 |
|GROSS PROF...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.